Konu "Non-Small Cell Lung Cancer" için Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed listeleme
Toplam kayıt 11, listelenen: 1-11
-
Clinicopathological factors in non-small cell lung cancer patients with bone metastases
(Elsevier Science, 2015)… -
Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study
(Zerbinis Publications, 2021)Purpose: In the literature there are conflicting data about the treatment efficacy of anaplastic lymphoma kinase (ALK) translocation positive non-small cell lung cancer (NSCLC) patients according to ALK fusion variants. ... -
The IL-25/ILC2 axis promotes lung cancer with a concomitant accumulation of immune-suppressive cells in tumors in humans and mice
(Frontiers Media SA, 2023)Background: Group 2 innate lymphoid cells (ILC2) can be activated by interleukin (IL)-33 or IL-25. IL-25-activated ILC2 cells help protect the host against helminth infection while exacerbating allergic-like inflammation ... -
Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
(Elsevier B.V., 2023)Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, ... -
Küçük hücreli dışı akciğer kanseri olgularının yoğun bakım mortalitesini öngörmede APACHE II ve MPM II-0 skorlarının rolleri: 8 yıllık deneyimimiz
(2022)Amaç: Küçük hücreli dışı akciğer kanseri (KHDAK) tüm akciğer kanseri olgularının yaklaşık %85’ini oluşturmaktadır. Bu çalışmada, KHDAK’lı hastaların yoğun bakım ünitesi (YBÜ) mortalite riskini öngörmede, Akut Fizyoloji ve ... -
The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer
(Biomed Central Ltd, 2013)Background: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of new diagnoses of pulmonary carcinoma. This study investigated the correlation between 18 F-fluorodeoxyglucose uptake in computerized tomography ... -
Outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical treatment
(Elsevier Science Inc, 2017)... -
Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: Multicenter experiences
(Asian Pacific Organization for Cancer Prevention, 2013)Surgery is the only curative treatment for operable non-small lung cancer (NSCLC) and the importance of adjuvant chemotherapy for stage IB patients is unclear. Herein, we evaluated prognostic factors for survival and factors ... -
Prognostic significance of protein kinase B/Akt pathway in patients with non-small cell lung cancer
(Zerbinis Medical Publications, 2014)Purpose: Akt, also known as protein kinase B (PKB), is an intracellular signal transduction protein activated by growth hormones. PKB/Akt is frequently activated in a variety of cancer types, but its role in the development ... -
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
(Elsevier Science Inc., 2021)Introduction: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer and in the absence of driver mutation preferred treatment is incorporation of immunotherapy.But for patients treated with chemotherapy ... -
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study
(Springer, 2022)Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ...